These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19597022)

  • 21. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
    Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
    Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
    Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New advance of the molecular targeting agents in advanced non-small cell lung cancer].
    Zhang L; Cheng ZW; Gao JM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):323-9. PubMed ID: 15266840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib or gefitinib for non-small-cell lung cancer.
    Kaye FJ; Jantz MA; Dallas J
    N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
    [No Abstract]   [Full Text] [Related]  

  • 25. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
    Hirsch FR; Bunn PA
    J Clin Oncol; 2005 Dec; 23(36):9044-7. PubMed ID: 16301593
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
    Costa DB; Kobayashi S
    J Clin Oncol; 2008 Feb; 26(4):686. PubMed ID: 18235134
    [No Abstract]   [Full Text] [Related]  

  • 28. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 30. Afatinib (Gilotrif) for advanced non-small cell lung cancer.
    Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556
    [No Abstract]   [Full Text] [Related]  

  • 31. EGFR inhibitors in the treatment of lung cancer.
    Hirsch FR
    Onkologie; 2007 Oct; 30(10):476. PubMed ID: 17890885
    [No Abstract]   [Full Text] [Related]  

  • 32. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulminant hepatic failure secondary to erlotinib.
    Liu W; Makrauer FL; Qamar AA; Jänne PA; Odze RD
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):917-20. PubMed ID: 17625975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
    Luo S; Chen L; Chen X; Xie X
    Oncotarget; 2015 Jun; 6(18):16725-34. PubMed ID: 26057469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
    Yamada K; Aono H; Hosomi Y; Okamoto H; Kato T; Komase Y; Nishikawa M; Azuma K; Takeoka H; Okuma Y; Nakahara Y; Sato A; Oba MS; Morita S; Kunitoh H; Watanabe K
    Eur J Cancer; 2015 Sep; 51(14):1904-10. PubMed ID: 26174465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
    Teh BW; Worth LJ
    Intern Med J; 2012 Nov; 42(11):1269-70. PubMed ID: 23157525
    [No Abstract]   [Full Text] [Related]  

  • 38. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Side effects of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)].
    Takeda K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():245-9. PubMed ID: 25831761
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
    Baselga J
    J Clin Oncol; 2002 May; 20(9):2217-9. PubMed ID: 11980990
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.